Why are we part of the @IKCCorg Global Patient Survey on #KidneyCancer? When local efforts are coupled with a global approach, we can have the greatest impact on improving health equity and patient outcomes for people affected by kidney cancer. bit.ly/IKCC_Kidney_Cancer_Gl… #AcceleratingCures

What role does genetics play in #KidneyCancer? Join us October 28 for a FREE KidneyCAN Town Hall exploring inherited cancer risk, genetic testing, and how emerging research could shape the future of kidney cancer care. Hear from leading experts, get answers to your questions, and connect with our community! 📅 October 28 | 5:30–6:30 PM ET 💻 Free via Zoom Register: kidneycan.org/genetics-kidne… #AcceleratingCures

The numbers are in! KidneyCAN Fall Advocacy Days brought together passionate advocates from across the country, all united by one goal: making sure the voices of the #KidneyCancer community are heard on Capitol Hill. Thank you to everyone who participated in Fall Advocacy Days and helped make this effort possible. Together, we're building momentum for a future with better treatments, more research, and better outcomes for people affected by kidney cancer. Our Advocacy Days may be over, but our work continues! 🧡 #AcceleratingCures

Could #KidneyCancer run in your family? At our October 28 Town Hall, our panelists will discuss hereditary kidney cancer, when genetic testing may be considered, and what patients and families should know about inherited risk. October 28 | 5:30–6:30 PM ET FREE via Zoom Register: kidneycan.org/genetics-kidne… #AcceleratingCures

Not every clinical trial is right for every patient. That's why finding relevant options starts with understanding more about YOU! The KidneyCAN Clinical Trial Navigator considers several important factors when identifying potential matches, including your diagnosis, your treatment history, your disease characteristics, and your location. Using this information, the Navigator helps identify clinical trials that may be relevant to your specific circumstances, making it easier to explore your options and discuss them with your care team. Ready to see what's out there? kidneycan.org/clinical-trial… #AcceleratingCures

Clinical trials may be available at many different points in the #KidneyCancer treatment journey, including before a patient begins their first systemic treatment. That’s why you don’t have to wait until you’ve run out of options to start learning about clinical trials. Exploring what’s available can help you understand what is being studied and give you more information to discuss with your healthcare team. The KidneyCAN Clinical Trial Navigator makes it easier to explore potential trial options based on your diagnosis, treatment history, and location. Start exploring: kidneycan.org/clinical-trial… #AcceleratingCures

📢 #KidneyCancer researchers: Don't miss this funding opportunity! The American Association for Cancer Research (AACR) Scholar-in-Training Awards (SITA) will support early-career investigators focused on kidney cancer research, helping them present their work, connect with leading experts, and advance their careers at the 2027 AACR Annual Meeting. 🚨 IMPORTANT: You must apply for AACR Associate Membership by TODAY, October 9, to be eligible! 🔗 Learn more and apply: bit.ly/SITA_2026 #AcceleratingCures

Only about 7% of patients with cancer in the U.S. participate in cancer treatment clinical trials. That matters, not only for the patients who may miss the opportunity to consider a clinical trial, but for the future of cancer care. Low participation can slow research, delay answers to important scientific questions, and make it harder to turn promising discoveries into new treatment options. One piece of the challenge is access. Finding trials that may fit an individual patient can be complicated, especially when trial information and eligibility requirements are difficult to navigate. The KidneyCAN Clinical Trial Navigator was created to make that process easier for people with kidney cancer. The free, AI-powered tool uses information about your diagnosis, treatment history, and location to help identify potential trial matches you can explore and discuss with your healthcare team. Better access to clinical trials can mean more opportunities for patients—and faster progress toward tomorrow’s kidney cancer treatments. Explore the Navigator: kidneycan.org/clinical-trial… #AcceleratingCures

Could #KidneyCancer run in your family? And what could advances in genetics mean for the future of kidney cancer care? Join us October 28 for our FREE Town Hall, Genetics and Kidney Cancer: From Family Risk to the Future of Patient Care. Hear from Dr. Brian Shuch, Dr. David Braun, and genetic counselor Lindsey Byrne, MS, LGC—and bring your questions! October 28 | 5:30–6:30 PM ET Community Social to follow Register: kidneycan.org/genetics-kidne… #AcceleratingCures

A #KidneyCancer diagnosis can affect the entire family. While caregivers often focus on supporting loved ones, their own needs matter too. As a caregiver for his wife, Mark learned that prioritizing his own well-being helped him show up more fully for the people he loves. Discover stories like Mark's, along with tailored resources to support caregivers on Kompass, a resource created in partnership with @kcCURE, @kidneycan, @KidneyCancer, @nkf, & @EisaiUS. Visit today: kidneycancerkompass.com/

This is the 5th @IKCCorg Global Patient Survey on Kidney Cancer, marking 10 years of collecting data specific to the experiences of people living with #KidneyCancer. This milestone makes it possible to track positive and negative trends and demonstrate changes over time. Add your experience today: bit.ly/IKCC_Kidney_Cancer_Gl… #AcceleratingCures

Finding clinical trials that may be relevant to you doesn’t have to feel overwhelming. Powered by AI and built specifically for people with #KidneyCancer, the Clinical Trial Navigator helps make complex clinical trial information easier to search and understand, so you can spend less time sorting through studies and more time having informed conversations about your care. Explore the free KidneyCAN Clinical Trial Navigator: kidneycan.org/clinical-trial… #AcceleratingCures

#KidneyCancer can bring a lot of questions, and you don’t have to navigate them alone. On Friday, October 9, the Judy Nicholson Foundation is bringing patients, caregivers, and kidney cancer experts together for "Hope in Motion: Empowering Patients and Caregivers," a FREE day of education, connection, and conversation. Throughout the day, experts will discuss topics that matter to people facing kidney cancer, including diagnosis and treatment options, new research, rare kidney cancers, clinical trials, imaging, nutrition, managing side effects, palliative care, and more. Most importantly, attendees will have opportunities to bring their own questions, hear directly from experts, and connect with other patients and caregivers who understand the kidney cancer experience. Registration is FREE, but space is limited! Learn more and reserve your seat: jnfkidneycancer.org/jax-symp… #AcceleratingCures

Need some direction when it comes to clinical trials? Introducing the KidneyCAN Clinical Trial Navigator—a free, AI-powered tool designed specifically to help people with #KidneyCancer explore clinical trials that may be relevant to them. Answer a few simple questions about your diagnosis, treatment history, and location, and the Navigator helps identify potential trial matches personalized to your situation. You can learn more about each trial, explore your options, and bring your results to your healthcare team for discussion. Start your search today: kidneycan.org/clinical-trial… #AcceleratingCures

Why participate in the Global Patient Survey on #KidneyCancer? The information gathered helps create education, support and advocacy programs that respond to the needs of people affected by kidney cancer. Take the survey: bit.ly/IKCC_Kidney_Cancer_Gl… #AcceleratingCures @IKCCorg

Clinical research. Translational research. You may hear both terms when learning about #KidneyCancer research, but what do they actually mean? While they approach research in different ways, both play an important role in advancing our understanding of kidney cancer and improving care for patients. Translational research helps bridge the gap between discoveries in the lab and potential applications for patients, while clinical research studies health, disease, and new approaches to care in people. And the two often work hand in hand. What researchers learn in the lab can help shape clinical studies, while observations from patients can lead to new questions and discoveries. #AcceleratingCures

NEWS: There’s a new treatment option for some people living with advanced #KidneyCancer. The FDA has approved the combination of belzutifan (Welireg, by @Merck) and lenvatinib (Lenvima, by @Eisai) for adults with advanced renal cell carcinoma (#RCC) with a clear cell component whose cancer has progressed after certain types of immunotherapy. Over the past decade, treatment options for advanced kidney cancer have grown significantly. But when cancer progresses after #immunotherapy, patients may face fewer options for what comes next. This FDA approval gives eligible patients another treatment option to discuss with their healthcare team. Dr. M. Catherine Pietanza, Vice President, Global Clinical Development, Merck Research Laboratories, says: “This approval represents real progress for patients and further reinforces the importance of a HIF-2α inhibitor plus TKI combination as a new treatment approach for these patients.” “Patients facing advanced renal cell carcinoma need treatment options at every stage of their journey, and the complexity of managing this disease over time makes every treatment decision meaningful,” said Dr. Corina Dutcus, Senior Vice President, Oncology Global Clinical Development Lead at Eisai. #AcceleratingCures

During KidneyCAN Advocacy Days, advocate Andrew Allers brought a deeply personal piece with him to the office of his representative, Congressman Jim Himes. Andrew is living with stage IV kidney cancer with brain metastases. His piece, Persistence, is a digital composite created from different slices of his own brain MRI, transforming part of his experience with cancer into a powerful visual representation of why continued progress in research matters. He left the piece with Congressman Himes' office, along with an artist statement that closes with a message at the heart of why we're here: “Cancer knows no party lines—funding for the research keeping people like me alive shouldn't either.” #AcceleratingCures

Every advancement in cancer care begins with research. On #WorldCancerResearchDay, we recognize the scientists, clinicians, patients, advocates, and supporters whose contributions help turn questions into discoveries. In #KidneyCancer, research has transformed our understanding of the disease and continues to open new possibilities for diagnosis, treatment, and care. But there is still more to learn and more progress to make. #AcceleratingCures

Today on World Cancer Research Day, KidneyCAN and @IKCCorg have launched the 2026-2027 Global Patient Survey on Kidney Cancer! All #kidneycancer patients, carers, and survivors are invited to share their experiences and insights in the online survey. bit.ly/IKCC_Kidney_Cancer_Gl… #AcceleratingCures